NEW YORK, November 13, 2013 /PRNewswire/ --
Editor Note: For more information about this release, please scroll to bottom.
Today, Analysts' Corner announced new research reports highlighting Merck & Co. Inc. (NYSE: MRK), Health Management Associates Inc. (NYSE: HMA), ZELTIQ Aesthetics, Inc. (NASDAQ: ZLTQ), MAKO Surgical Corp. (NASDAQ: MAKO), and Amarin Corporation plc (NASDAQ: AMRN). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Merck & Co. Inc. Research Report
On November 9, 2013, Merck & Co. Inc. (Merck) announced data for its investigational Timothy grass sublingual allergy immunotherapy tablet (MK-7243) from a study involving 1,501 North American adult and pediatric patients. According to Merck, results showed that MK-7243 significantly improved Total Combined Score (TCS) averaged over the entire grass pollen season (the primary endpoint), which was the sum of the rhinoconjunctivitis daily symptom score (DSS) and the daily medication score (DMS), compared to placebo. The Company further informed that the results of this study will be presented in a poster titled "Efficacy and Safety of MK-7243: A Grass Sublingual Immunotherapy Tablet Treatment in a Large Randomized Controlled Trial in North American Children and Adults" on November 9, 2013, from 12:30 - 1:30 p.m. ET, and on November 10, 2013, from 12:30 - 1:30 p.m. ET. The Full Research Report on Merck & Co. Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Health Management Associates Inc. Research Report
On November 5, 2013, Health Management Associates Inc. (HMA) announced that it will restate its financial statements for the years ended December 31, 2010, 2011 and 2012 and the quarters ended March 31 and June 30, 2013 to correct the accounting treatment of approximately $31.0 million of Medicare and Medicaid Health Information Technology (HCIT) payments recognized as income between July 1, 2011 and June 30, 2013. The Company disclosed that it intends to file the necessary amendments to its prior filings at the earliest, following which the Company will file its Quarterly Report on Form 10-Q for the quarter ended September 30, 2013. According to HMA, it has concluded that, due solely to this matter, its financial statements and related communications for FY 2010, FY 2011 and FY 2012 as well as for the fiscal quarters ended March 31, 2013 and June 30, 2013, along with its annual 2013 guidance issued on July 30, 2013, should no longer be relied upon. The Company has filed a Current Report on Form 8-K containing additional information concerning this matter. HMA also reported that it is not providing annual guidance for 2013, at this time, and the previously issued guidance provided on July 30, 2013 has been withdrawn. The Full Research Report on Health Management Associates Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
ZELTIQ Aesthetics, Inc. Research Report
On November 7, 2013, ZELTIQ Aesthetics, Inc. (ZELTIQ) announced that it has priced an underwritten public offering of 4.5 million shares of its common stock at a price to the public of $13.00 per share, with all the shares being offered by selling stockholders. Underwriters have a 30-day option to purchase up to 675,000 additional shares. The Company reported that Goldman Sachs & Co. and J.P. Morgan Securities LLC are acting as joint book-running managers with Canaccord Genuity Inc. and William Blair & Company, LLC acting as co-managers for the said offering. The Full Research Report on ZELTIQ Aesthetics, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
MAKO Surgical Corp. Research Report
On November 5, 2013, MAKO Surgical Corp. (MAKO) reported its financial results for Q3 2013. Total revenue decreased 22.0% YoY to $22.8 million. Net loss was $21.3 million or $0.45 per diluted share, compared to $6.6 million or $0.15 per diluted share in Q3 2012. Commenting on the results, President and CEO Maurice R. Ferré, MD, said, "MAKO's attention to the Stryker and Pipeline transactions in the final month of the third quarter, in combination with the announcement on September 25 of the pending MAKO - Stryker merger, had an appreciable effect on our operating results for the quarter, especially with respect to sales of RIO systems." The Full Research Report on MAKO Surgical Corp. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Amarin Corporation plc Research Report
On November 7, 2013, Amarin Corporation plc (Amarin) reported its financial results for Q3 2013. Net loss was $48.9 million or $0.29 per diluted share, compared to net loss of $26.4 million or $0.18 per diluted share in Q3 2012. Chairman and CEO Joseph Zakrzewski said, "We continue to witness the growth of awareness, Tier 2 managed care conversions, and prescription volume for Vascepa, seeing an increase of 58% in normalized TRxs from Q2 to Q3 of this year. We believe our dedicated and talented employees will be able to continue to grow our commercial business. We also believe that the efficacy and safety profile of Vascepa for its approved indication reflects a unique and favorably differentiated product which is well positioned to help clinicians provide improved care to their patients." The Full Research Report on Amarin Corporation plc - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts' Corner